

PHILIPS

K972103

Philips Medical Systems

510(k) Summary of Safety and Effectiveness

SEP - 2 1997

Company Name:

Philips Medical Systems North America Company

Address:

710 Bridgeport Avenue Shelton, CT 06484

Contact Person:

Peter Altman

Telephone Number:

203-926-7031

Prepared:

June 24, 1997

Device Name:

Philips Easyvision Family Workstation Option

MR Cardiac Analysis Package

Classification Name:

Image Processing System

(90 LLZ)

Common/Usual Name:

Workstation

Predicate Devices:

Philips Gyroview HR (K921219)

GE Advantage Windows Review Workstation

(K960613, K942120, and K913770).

Philips Gyroscan Rel 2 MR Systems

(K920578 and K920791)

Intended Use:

The MR Cardiac Analysis Package is intended for use in processing cardiac or cardiovascular MR images, resulting in quantitative and/or qualitative data that can be used to estimate cardiac or cardiovascular function.

System Description:

Quantitative analysis of MR Cardio exams is normally a tedious and time consuming procedure. The MR Cardiac Analysis Package provides off-line viewing and processing functions for cardiac and cardio-vascular examinations, acquired with Magnetic Resonance, to simplify the process.

Historically the user had to outline the end-systolic and end-diastolic ventricle areas in one or all slices. To reduce the time required for the analysis, the **MR Cardiac**Analysis Package provides a facility for computer assisted detection of the heart boundaries of the left ventricle. The user may edit the computer generated boundary and must always approve the selection. The right ventricle boundary must still be detected manually.

To use the MR Cardiac Analysis Package, MR images of the heart are acquired with dedicated MR sequences at multiple slices and different phases of the heart cycle and transferred to the Easyvision Workstation. Processing these images provides data that can be used to estimate various quantitative parameters, e.g., ejection fraction, stroke volume, diastolic and systolic volume, ventricular mass, and wall thickness. It can also provide a display of cardiac functional parameters and permits correction for errors caused by papillary muscle. All quantitative results can be printed in a dedicated, user definable, print layout for cardiac analysis, where analysis data (statistical and graphical) can be reported in combination with the image data.

The package will also provide viewing capabilities such as direct access to images, defined by slice location or heart phase, and synchronized movies for the different heart phases and/or slices.



Food and Drug Administration. 2200 Corporate Boulevard
Rockville MD 20850

Peter Altman
Director of Regulatory Affairs
Philips Medical Systems
North America Company
710 Bridgeport Avenue
P.O. Box 860
Shelton, CT 06484-0917

Re: K972103

Easy Vision Family Workstation Option: MR Cardiac Analysis

Software Package Dated: June 2, 1997

Received: June 4, 1997

SEP - 2 1997

Unclassified Procode: 90 LLZ

Dear Mr. Altman:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the <u>Code of Federal Regulations</u>, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Li!lian Yin, Ph.D.

Director, Division of Reproductive,

Abdominal, Ear, Nose and Throat, and Radiological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

510(k) Number (if known): Unknown K972/83	
Device Name: Philips EasyVision Workstation MR Cardiac Analysis Option	<u>n</u>
Indications For Use:	
The MR Cardiac Analysis Package is indicated for use in association with cardiac an cardiovascular examinations where it is useful or necessary to perform qualitative quantitative analysis.	
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED))
Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number	
Prescription Use OR Over-The-Counter Use (Per 21 CFR 801.109 (Optional Format 1-2-96	6)